Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented Indian Pharma Company with presence in 55 countries. Indoco, a USD 166 million company, employs over 6000 people including over 300 skilled scientists.
The company has 9 manufacturing facilities, out of which 6 are for finished dosages and 3 for APIs and supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, MOH Botswana, TGA-Australia, NMRA - Sri Lanka, FMHACA-Ethiopia, SUKL – Czech Republic, DPML- Ivory Coast, SAHPRA- South Africa, NDA-Uganda, MOH – Oman, INVIMA - Colombia, Health Canada, TFDA-Tanzania, MCA- Zimbabwe, MOHP UAE, ANVISA-BRAZIL, MOH-Yemen, NMPB- Sudan, OGYEI-Hungary, MOH-Ukraine, PPB-Kenya, NAFDAC - Nigeria, ZAMRA- Zambia, MOHP- Qatar, NMRC -Namibia and FDA-Ghana.
Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.
Indoco Analytical Solutions (IAS) division has been carved to serve customers for their analytical research needs, utilizing the state-of-the-art instruments/infrastructure and highly experienced human resources.
AnaCipher CRO, based in Hyderabad, is a USFDA inspected clinical research facility and is spread over 30,000 sq. ft area and staffed by experienced professionals providing clinical trial solutions, including bioavailability and bioequivalence (BA/BE)/Phase I/Phase II studies for pharmaceutical companies globally.
With one foot firmly entrenched in the fast growing Indian Pharma Market and the other in the vast International market, Indoco is beautifully poised to achieve greater heights.
The company has 9 manufacturing facilities, out of which 6 are for finished dosages and 3 for APIs and supported by a state-of-the-art R&D centre at Rabale, Navi Mumbai. The facilities have been approved by various regulatory authorities such as USFDA, UK-MHRA, MOH Botswana, TGA-Australia, NMRA - Sri Lanka, FMHACA-Ethiopia, SUKL – Czech Republic, DPML- Ivory Coast, SAHPRA- South Africa, NDA-Uganda, MOH – Oman, INVIMA - Colombia, Health Canada, TFDA-Tanzania, MCA- Zimbabwe, MOHP UAE, ANVISA-BRAZIL, MOH-Yemen, NMPB- Sudan, OGYEI-Hungary, MOH-Ukraine, PPB-Kenya, NAFDAC - Nigeria, ZAMRA- Zambia, MOHP- Qatar, NMRC -Namibia and FDA-Ghana.
Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.
Indoco Analytical Solutions (IAS) division has been carved to serve customers for their analytical research needs, utilizing the state-of-the-art instruments/infrastructure and highly experienced human resources.
AnaCipher CRO, based in Hyderabad, is a USFDA inspected clinical research facility and is spread over 30,000 sq. ft area and staffed by experienced professionals providing clinical trial solutions, including bioavailability and bioequivalence (BA/BE)/Phase I/Phase II studies for pharmaceutical companies globally.
With one foot firmly entrenched in the fast growing Indian Pharma Market and the other in the vast International market, Indoco is beautifully poised to achieve greater heights.
Location: India, Maharashtra, Mumbai
Employees: 5001-10000
Founded date: 1947
Investors 1
| Date | Name | Website |
| - | Baring Pri... | bpepindia.... |
Mentions in press and media 4
| Date | Title | Description |
| 03.02.2026 | Q3 Results Today Live: MobiKwik turns profitable in Q3, Indoco loss widens, AWL Agri profit down, Bajaj Finance, Adani Ports, Adani Enterprises, Solar Ind, Pidilite Ind, Aether Ind, Bharat Coking Coal... | Two investors are working together with analyzing the stock data graphs in the paper and viewing the data on the laptop screen. istock photo for BL | Photo Credit: wutwhanfoto Q3 Results Today, 03rd Feb 2026 Live Updates: Find all the lates... |
| 28.07.2025 | JK Paper to acquire majority stake in Borkar Packaging, expands folding carton footprint | Credit: Pexels JK Paper Ltd, a unit of the Singhania family-led JK Group, has agreed to acquire a controlling stake in folding carton manufacturer Borkar Packaging Pvt Ltd, marking its fifth acquisition in the sector in three years. The pap... |
| 02.05.2024 | India, New Zealand look to boost collaboration in pharma, digital trade | - |
| 25.03.2024 | Indoco Remedies’ subsidiary commences production of pharmaceutical intermediates | Indoco Remedies’s wholly-owned subsidiary, Warren Remedies Pvt Ltd, has commenced commercial production of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) at its greenfield manufacturing facility at Aurangabad, Mah... |